Xenogen is Next Piece in Caliper s Discovery Continuum ; High-Content Play is on Horizon | GenomeWeb

Caliper Life Sciences this week announced that it will acquire small-animal imaging firm Xenogen in a bid to broaden its palette of drug-discovery tools and hopefully generate what it estimates to be 10 percent to 15 percent top-line growth for the combined company.

The $80 million deal provides Caliper its first taste of an imaging platform for drug discovery, and falls in line with the company's strategy to be a complete pipeline drug-discovery tools and service vendor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.